Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16069
Abstract: Venetoclax is an oral, highly selective BCL2 inhibitor with significant clinical efficacy in a range of B-cell lymphoproliferative disorders, including chronic lymphocytic leukaemia (CLL) (Roberts et al, 2016; Seymour et al, 2017), mantle cell lymphoma… read more here.
Keywords: bcl2 mutations; venetoclax; resistance; bcl2 ... See more keywords